Ixmyelocel-T - Vericel

Drug Profile

Ixmyelocel-T - Vericel

Alternative Names: Bone Repair Cells - Vericel Corporation; BRC therapy - Vericel Corporation; Cardiac Repair Cells - Vericel Corporation; CRC therapy - Vericel Corporation; Tissue Repair Cells - Vericel Corporation; Tissue repair stem cell therapy - Vericel Corporation; TRC therapy - Vericel Corporation; Vascular Repair Cells - Vericel Corporation; VRC therapy - Vericel Corporation

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aastrom Biosciences
  • Developer Aastrom Biosciences; University of Michigan; Vericel Corporation
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteonecrosis; Dilated cardiomyopathy
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alveolar bone loss; Dilated cardiomyopathy
  • Suspended Peripheral ischaemia
  • No development reported Atherosclerosis; Neurodegenerative disorders
  • Discontinued Non-union fracture; Osteoarthritis; Osteonecrosis; Osteoporosis; Vertebral fracture

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in USA
  • 10 May 2017 Ixmyelocel-T licensed to Innovative Cellular Therapeutics in China, South Korea, Singapore, and other countries in South East Asia
  • 10 May 2017 Ixmyelocel-T receives Regenerative Medicine Advanced Therapy (RMAT) designation from US FDA for Dilated cardiomyopathy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top